Based on numerous ongoing clinical studies for exploring the possible synergy of immunotherapy combined with conventional cancer treatments, we selected the combined therapy, i.e., chemotherapy plus anti-PD-1 therapy (Figure 1A). The gene discussed is PDCD1; the disease is cancer.